Cellectis bioresearch and Lonza Enter Development and Commercial Manufacturing Agreement
Advertisement
Cellectis bioresearch, subsidiary of Cellectis, and Lonza announced that the companies have entered into an agreement for the development and commercialization of a bioengineered cell line.
Cellectis bioresearch will use its meganucleases to deactivate (knock-out) the glutamine synthetase (GS) in CHOK1SV, Lonza’s proprietary host cell line. Meganucleases are molecular scissors that can be directed to a single highly specific site in the genome of a cell, thereby allowing a wide range of precise genome modifications, including targeted gene integration, gene knock-out as well as modulation of gene function.